Table 2 Treatment modifications
FAS population | |
|---|---|
Dose interruptionsa: n (%) | 204 (31.2) |
Reasons: n (%) | |
Patient willingness | 8 (3.9) |
General health deterioration | 29 (14.2) |
Adverse event (treatment-related or not) | 173 (84.8) |
Other | 9 (4.4) |
Dose reduction: n (%) | 278 (42.5) |
Reasons: n (%) | |
Patient willingness | 6 (2.2) |
General health deterioration | 66 (23.7) |
Disease progression | 2 (0.7) |
Adverse event (treatment-related or not) | 226 (81.3) |
Other | 20 (7.2) |
Any kind of dose modification: n (%) | 329 (50.3) |